GLP-1 receptors are widely distributed throughout the body including the pancreas, gastrointestinal tract, and central nervous system, which helps explain both their broad therapeutic benefits and their diverse clinical effects
The market projections are staggering with 135 million worldwide users by the end of this decade
According to the CDC, those with a normal BMI are recommended to gain 25 to 35 pounds (while those with overweight or obesity are recommended to gain slightly less)
Sound mechanistic evidence supports the need for further research on the GLP1-RAs/SGLT2is combinations ability to modify specific risk outcomes, such as cardiovascular risk and the progression of diabetic kidney disease
The medication works particularly well for patients with food cravings, emotional eating, or portion control issues, as the appetite suppression effects can be profound